510 related articles for article (PubMed ID: 26094107)
1. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.
Hung SC; Chang YK; Liu JS; Kuo KL; Chen YH; Hsu CC; Tarng DC
Lancet Diabetes Endocrinol; 2015 Aug; 3(8):605-14. PubMed ID: 26094107
[TBL] [Abstract][Full Text] [Related]
2. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study.
Lazarus B; Wu A; Shin JI; Sang Y; Alexander GC; Secora A; Inker LA; Coresh J; Chang AR; Grams ME
JAMA Intern Med; 2018 Jul; 178(7):903-910. PubMed ID: 29868840
[TBL] [Abstract][Full Text] [Related]
3. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.
Marcum ZA; Forsberg CW; Moore KP; de Boer IH; Smith NL; Boyko EJ; Floyd JS
J Gen Intern Med; 2018 Feb; 33(2):155-165. PubMed ID: 29181788
[TBL] [Abstract][Full Text] [Related]
4. Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
Inzucchi SE; Lipska KJ; Mayo H; Bailey CJ; McGuire DK
JAMA; 2014 Dec 24-31; 312(24):2668-75. PubMed ID: 25536258
[TBL] [Abstract][Full Text] [Related]
5. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.
Kwon S; Kim YC; Park JY; Lee J; An JN; Kim CT; Oh S; Park S; Kim DK; Oh YK; Kim YS; Lim CS; Lee JP
Diabetes Care; 2020 May; 43(5):948-955. PubMed ID: 32132005
[TBL] [Abstract][Full Text] [Related]
6. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study.
Gamble JM; Chibrikov E; Twells LK; Midodzi WK; Young SW; MacDonald D; Majumdar SR
Lancet Diabetes Endocrinol; 2017 Jan; 5(1):43-52. PubMed ID: 27865756
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of lactic acidosis-related parameters upon and after metformin discontinuation in patients with diabetes and chronic kidney disease.
Sipahi S; Solak Y; Acikgoz SB; Genc AB; Yildirim M; Yilmaz U; Nalbant A; Tamer A
Int Urol Nephrol; 2016 Aug; 48(8):1305-1312. PubMed ID: 27102431
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
Chu PY; Hackstadt AJ; Chipman J; Griffin MR; Hung AM; Greevy RA; Grijalva CG; Elasy T; Roumie CL
Diabetes Care; 2020 Jul; 43(7):1462-1470. PubMed ID: 32327421
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan.
Chang CH; Sakaguchi M; Dolin P
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1196-1203. PubMed ID: 27221971
[TBL] [Abstract][Full Text] [Related]
10. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
[TBL] [Abstract][Full Text] [Related]
11. Therapy: Risk of metformin use in patients with T2DM and advanced CKD.
Schernthaner G; Schernthaner-Reiter MH
Nat Rev Endocrinol; 2015 Dec; 11(12):697-9. PubMed ID: 26284445
[TBL] [Abstract][Full Text] [Related]
12. Metformin: time to review its role and safety in chronic kidney disease.
Tanner C; Wang G; Liu N; Andrikopoulos S; Zajac JD; Ekinci EI
Med J Aust; 2019 Jul; 211(1):37-42. PubMed ID: 31187887
[TBL] [Abstract][Full Text] [Related]
13. [Proposal for the modification of metformin use in patients with chronic kidney disease].
Balogh Z; Mátyus J
Orv Hetil; 2012 Sep; 153(39):1527-35. PubMed ID: 23000419
[TBL] [Abstract][Full Text] [Related]
14. Chronic kidney disease: Metformin increases risk of mortality in patients with advanced chronic kidney disease.
Edwards JK
Nat Rev Nephrol; 2015 Aug; 11(8):443. PubMed ID: 26149836
[No Abstract] [Full Text] [Related]
15. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study.
Eppenga WL; Lalmohamed A; Geerts AF; Derijks HJ; Wensing M; Egberts A; De Smet PA; de Vries F
Diabetes Care; 2014 Aug; 37(8):2218-24. PubMed ID: 24842984
[TBL] [Abstract][Full Text] [Related]
16. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.
Whitlock RH; Hougen I; Komenda P; Rigatto C; Clemens KK; Tangri N
Mayo Clin Proc; 2020 Jan; 95(1):90-100. PubMed ID: 31902433
[TBL] [Abstract][Full Text] [Related]
17. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
[TBL] [Abstract][Full Text] [Related]
18. Metformin therapy in patients with chronic kidney disease.
Duong JK; Roberts DM; Furlong TJ; Kumar SS; Greenfield JR; Kirkpatrick CM; Graham GG; Williams KM; Day RO
Diabetes Obes Metab; 2012 Oct; 14(10):963-5. PubMed ID: 22564555
[TBL] [Abstract][Full Text] [Related]
19. Limitations of metformin use in patients with kidney disease: are they warranted?
Vasisht KP; Chen SC; Peng Y; Bakris GL
Diabetes Obes Metab; 2010 Dec; 12(12):1079-83. PubMed ID: 20977579
[TBL] [Abstract][Full Text] [Related]
20. Mortality and metformin use in patients with advanced chronic kidney disease.
Lalau JD; Kajbaf F; Arnouts P; de Broe M
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):680-1. PubMed ID: 26298570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
